Floatz logo

Eloxatin

Huntington's Disease

Massachusetts General HospitalPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Huntington's Disease cohort.

Asset / SponsorPhaseRating
Tetrabenazine
William Ondo, MD
Phase 4BBB
Dimebon
Medivation, Inc.
Phase 3BB
sen0014196
Siena Biotech S.p.A.
Phase 2BB
coq10
Johns Hopkins University
Phase 3B
FLUOROURACILUM
Massachusetts General Hospital
Phase 3B

View all 32 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →